Dallas Buyers Club

Quote

Anonymous

Guest
I watched the dallas buyers club this weekend. It reminded me of my time at vertex. Selling a toxic drug that was killing people. What were we thinking? All in the face of greed. Omg! Insanity!!!
 






Anonymous said:
I watched the dallas buyers club this weekend. It reminded me of my time at vertex. Selling a toxic drug that was killing people. What were we thinking? All in the face of greed. Omg! Insanity!!!
Click to expand...

Yup. The "it's all for the patients" PR stunts are B.S. Anybody who has worked here for a while knows it's all about money and greed. Leadership only cares about making $$$ not the well being of patients or employees
 












Anonymous said:
I watched the dallas buyers club this weekend. It reminded me of my time at vertex. Selling a toxic drug that was killing people. What were we thinking? All in the face of greed. Omg! Insanity!!!
Click to expand...


Vertex killed hundreds if not thousands of patients. Some of them had their skin fall off. Pathetic.

I remember even at the end my manager forcing us to "get scripts"
 












It is what it is...and we did our best. Now let's move on.


Victrelis, Incivek Yield Low Hep C Cures Among Cirrhosis



Victrelis (boceprevir)- or Incivek (telaprevir)-based triple therapy for hepatitis C virus (HCV) resulted in low cure rates and high rates of serious side effects among those most in need of treatment: people with cirrhosis, aidsmap reports. Investigators presented findings of a study of 221 people with genotype 1 of the virus at the International Liver Congress, the 48th annual meeting of the European Association for the Study of the Liver (EASL) in Amsterdam.

Participants were treated with either of the two currently available protease inhibitors, Victrelis or Incivek, plus pegylated interferon or ribavirin for 48 weeks. All participants had failed a previous therapy. Those taking Incivek took the triple regimen for 12 weeks followed by 36 weeks of just interferon and ribavirin. Those taking Victrelis took the drug for four weeks alone and then added the other two drugs for an additional 44 weeks.

Cure rates were low, with only 41 percent of those who took Victrelis and 40 percent of those who took Incivek achieving a sustained virologic response (SVR, considered a cure) 12 weeks after completing therapy.

Fifty-four percent of those who took Incivek and 51 percent of those who took Victrelis experienced serious adverse events. Twenty-one percent of those on Incivek discontinued treatment because of adverse events compared with 11 percent for Victrelis.

The study had a 2.4 mortality rate in the Incivek arm and a 1.6 percent rate in the Victrelis arm.
 






























Top Bottom
Back
Quote